Deep knowledge on
small-molecule drugs and
the 90,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Drug Master File Entries: see list||80|
|Suppliers / Packaging: see list||34|
|Therapeutic Class:||Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)|
Inflammatory Bowel Disease Agents
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
prednisolone acetate; sulfacetamide sodium
|OINTMENT;OPHTHALMIC||010210-002||Sep 9, 1984||DISCN||No||<disabled>||<disabled>|
|INJECTABLE;INJECTION||083738-001||Approved Prior to Jan 1, 1982||DISCN||No||<disabled>||<disabled>|
|SUSPENSION;ORAL||022067-001||Jan 17, 2008||DISCN||No||6,071,523||<disabled>||Y||<disabled>|
|This preview shows a limited data set|
Subscribe for full access, or try a Trial
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.